about
Neurocognitive function in HIV-infected patients: comparison of two methods to define impairmentHIV-1 DNA predicts disease progression and post-treatment virological control.Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients.Neurocognitive function in HIV infected patients on antiretroviral therapyDuration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.Factors influencing lopinavir and atazanavir plasma concentration.Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.Evaluation of cerebrospinal fluid virological escape in patients on long-term protease inhibitor monotherapy.The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels.Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy.Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.Late effects surveillance system for sarcoma patients.Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy.Almost normal cognitive function in patients during therapy for childhood acute lymphoblastic leukemia without cranial irradiation according to ALL-BFM 95 and COALL 06-97 protocols: results of an Austrian-German multicenter longitudinal study and imHydrochlorothiazide in CLDN16 mutation.Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: A report from the Late Effects Surveillance SystemGlomerular dysfunction and associated risk factors over 4–5 years following antiretroviral therapy initiation in AfricaPatient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 TrialEffect of renal failure and dialysis on circulating ghrelin concentration in childrenCirculating resistin concentrations in children depend on renal functionProspective evaluation of hepatitis B, C and HIV infections as possible sequelae of antineoplastic treatment in paediatric sarcoma patients: a report from the Late Effects Surveillance SystemGrowth impairment after ifosfamide-induced nephrotoxicity in children
P50
Q33982015-160E10D2-A14A-4A97-9EB4-15822EC15EB5Q34350410-7F5AAF60-E48C-4E3E-9588-724B2937A7D1Q34475281-8E7C9687-D1AF-4A80-AFE1-0DB87B020F7AQ34706686-A78B0493-7287-4ABA-961C-F1E732757445Q35036284-3673BB5D-09C6-4153-A7D2-A6B6FB17F54DQ35431516-B863D4EB-DFBA-4AFA-9B49-90FD88A49E8FQ35961111-D0BFCA8F-A220-406E-B8C3-886C741D4301Q36012177-1EEB207E-01C3-4608-91DA-B03BC694BC60Q36446900-4CD36DBE-5102-4220-8416-9AF4828B7A85Q36613143-E746538B-918A-4638-8924-5CA178CFFB07Q37055030-0CCC2A08-03F1-402F-B580-450FB0BB3FECQ37476403-45D81621-6A75-451D-953E-72592C187D58Q37613230-BCE8C508-0D01-4C52-AAD9-0C1A54C0F2D8Q38875495-413665D6-5B0E-4E25-90A1-4B921EBB5B02Q38878471-FA448DA5-FC28-459E-B613-E22251F29969Q38879115-4543E97F-BC28-4A30-AB3B-5962F122A100Q39043240-8E57F7D5-7FE6-4DDD-AD47-7808D4FB1A0BQ39281972-FDA3C25B-F2C0-43A1-8989-E14D0038E0BEQ39929987-063AA342-8545-4667-A503-03864F877BF8Q40485975-6020869A-0CFE-4DAB-B3B2-A6D40EC74C29Q42273597-6D6CCEA0-386A-4E97-8106-5B65B01E7176Q43169897-FDE37583-B4A9-473D-A63E-716FB16EAF9DQ43474735-273B1390-C5A0-4529-B59A-E41FCCD122EDQ44048358-0935EA7A-7F40-4AA3-A081-13CCAF2C6177Q44766169-62C91C76-D358-4482-A915-B6056233573FQ46038788-0D3F4882-BA10-4831-855F-3EDC22B65E88Q46236792-46CA0601-E28E-4F4D-81CC-8FDD04E5BBB0Q46576663-0AB854EE-AC90-42C0-AB75-B619A29352A0Q50049305-6F7A5370-3BDC-4A18-A80F-DD95D65215DFQ51755891-3973C8A0-9E71-47AA-B3FA-FD15B7ED8E62Q51811932-5524943A-08F6-4B81-9877-F18E5FBF4E95Q57339555-BE7437A3-23C4-49BA-89C9-C7F76467BF02Q57972122-8F77C9C5-A664-4826-91BD-4C12A041FAD0Q58549540-C5305139-71C6-4144-A9A0-AB07FF1095F8Q80337592-FD29748B-C5F6-4C84-8DC3-B8B8095D8AC9Q81168412-66E3E63F-ACE2-4103-8F95-7B296790EE37Q82499385-FAC800FA-2770-4FE1-9FD1-BF174B7E08C2Q83931939-5C036020-7741-4DB5-9F4E-3B7CCF3BE1FB
P50
name
Wolfgang Stöhr
@en
type
label
Wolfgang Stöhr
@en
prefLabel
Wolfgang Stöhr
@en